1. Market Research
  2. > Healthcare Market Trends
  3. > Indonesia Pharmaceutical & Healthcare Industry Report - 2016

Indonesia Pharmaceutical & Healthcare Industry Report - 2016

  • March 2016
  • -
  • Emerging Markets Direct Media Holdings
  • -
  • 30 pages

This report profiles Indonesia's pharmaceutical and healthcare industry, discussing market trends through 2015 and outlook for 2016 and beyond. The report also highlights leading players in the sector including Kalbe Farma, Techno Scan Pacific and Kimia Farma.



The Indonesian pharmaceutical and healthcare sector has recorded double digit growth over the last few years. However, in value terms, domestic pharmaceutical industry was minuscule in size compared to the markets of the U.S. and Japan. Low per capita income, subsidies, lower penetration and accessibility of healthcare were the main reasons for this low figure. Hence, immense potential exists for the growth of domestic pharmaceutical sector. However, the sector is often marred by regulatory flip flops, drug approval delays, currency fluctuations, unethical practices and pricing controls.



In 2015, the sector saw a challenging period due to lower economic growth and higher inflation. Depreciation of IDR, higher electricity tariffs and higher minimum wages also led to an erosion in the profitability margins of pharmaceutical manufacturers during the year. However, the implementation of the National Health Insurance (JKN) program by the Social Security Agency (BPJS) in 2014 helped to revive the sector. The growth was backed majorly by the generics segment. The JKN program has made Indonesia one of the fastest growing pharmaceuticals markets in the region. Both domestic and foreign companies are expanding their production capacities to meet the expected demand growth over the next few years thanks to the program.



Going forward, the sector is expected to be back on double-digit growth path, backed by government support and various macro growth drivers, including rise in per capita income, rise in health insurance penetration, proliferation of healthcare services across the remote areas, increase in foreign investments and increase in government as well as private expenditure on health. However, frequent policy changes and rising prices of raw materials may act as deterrents for the growth of this sector.



Key Points:



o Government accounted for around 40% of the total healthcare spending while the private sector accounted for the remainder. The healthcare market saw a CAGR of around 20% during 2006-2011 and is expected to surpass USD 30bn by 2015.



o The government aims to have every Indonesian covered by health insurance before 2019 under the new program Jaminan Kesehatan Nasional (JKN), with nearly IDR 20tn (US$1.6 billion) allocated to cover premiums for the poor in 2014. The scheme was launched on Dec 31, 2013 by President Susilo Bambang Yudhoyono.



o Indonesian companies accounted for 70% of the pharmaceutical market while foreign companies accounted for the remainder. The pharmaceutical market grew at a CAGR of 12% during 2007-12. In 2013, it remained stagnant in USD terms. However, the sector recovered in 2014, recording a growth of 21% y/y. It further grew by 13% in 2015.



o Indonesia had an average GDP growth rate of 5.9% during 2006-2012. However, FY15 proved to be tough for the economy with GDP slowing to a five-year low of 4.8%. However, the healthcare sector was resilient even amidst the dip in the overall economy.

Table Of Contents

Indonesia Pharmaceutical and Healthcare Industry Report - 2016
1. Industry Profile

1.1 Sector overview

1.2 Sector size

1.3 Competitive landscape

1.4 Environmental scanning



2. Market Trends and Outlook

2.1 Key economic indicators-Indonesia

2.2 Health status indicators

2.3 Healthcare infrastructure

2.4 Investments

2.5 Market outlook



3. Leading Players and Comparative Matrix

3.1 Leading players

3.1.1 PT Kalbe Farma Tbk (Kalbe)

3.1.2 PT Tempo Scan Pacific Tbk (TSP)

3.1.3 PT Kimia Farma (Persero) Tbk (Kimia)

3.2 Comparative matrix

3.3 SWOT analysis



4. Tables and Charts

Table 1: World health financing statistics

Table 2: Functions of the BPOM

Table 3: Key financial ratios of the leading players



Chart 1: Breakup of global pharmaceutical market by country

Chart 2: Size of Indonesian healthcare industry

Chart 3: Size of Indonesian pharmaceutical industry

Chart 4: Market share of different players in the pharmaceutical sector of Indonesia

Chart 5: Position of People's Representative Council after 2014 elections

Chart 6: Per capita expenditure on health

Chart 7: Pharmaceutical market breakdown

Chart 8: Annual budget for government healthcare spending

Chart 9: Quarterly GDP growth rate-Indonesia

Chart 10: Trade balance of Indonesia

Chart 11: Average monthly USD to IDR exchange rate

Chart 12: Government budget deficit

Chart 13: CPI Inflation-Indonesia

Chart 14: BI rate-Indonesia

Chart 15: Child mortality rate (under 5 Years) per 1000 live births

Chart 16: Maternal mortality rate per 100,000 live births

Chart 17: Infant mortality rate (under 1 year) per 1000 live births

Chart 18: Countries with highest number of people living with HIV infections

Chart 19: Deaths due to tuberculosis among HIV-negative people

Chart 20: Causes of mortality in Indonesia

Chart 21: Number of doctors in Indonesia

Chart 22: Number of hospital beds per 1000 persons

Chart 23: Forecast for the size of Indonesian pharmaceutical sector

Chart 24: Sales breakdown by segment-Kalbe

Chart 25: Net sales of Kalbe

Chart 26: Profit margin of Kalbe

Chart 27: Sales breakdown by segment-TSP

Chart 28: Net sales of TSP

Chart 29: Profit margins of TSP

Chart 30: Sales breakdown by segment-Kimia

Chart 31: Net sales of Kimia

Chart 32: Profit margins of Kimia

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Automated Microbiology Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Volume and Sales Forecasts for 100 Molecular Diagnostic Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Automated Microbiology Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Volume and Sales Forecasts for 100 Molecular Diagnostic Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 52500
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 75-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...

2017 Europe Diagnostics Market Forecasts: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2017 Europe Diagnostics Market Forecasts: Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

  • $ 47500
  • Industry report
  • January 2017
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides granular analysis of the Europe diagnostic testing market, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.